{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T04:06:15Z","timestamp":1784779575919,"version":"3.55.0"},"reference-count":32,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Venetoclax is an effective treatment for certain blood cancers, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). However, most patients relapse while on venetoclax and further treatment options are limited. Combining venetoclax with immunotherapies is an attractive approach; however, a detailed understanding of how venetoclax treatment impacts normal immune cells in patients is lacking. In this study, we performed deep profiling of peripheral blood (PB) cells from patients with CLL and AML before and after short-term treatment with venetoclax using mass cytometry (cytometry by time of flight) and found no impact on the concentrations of key T-cell subsets or their expression of checkpoint molecules. We also analyzed PB from patients with breast cancer receiving venetoclax long-term using a single-cell multiomics approach (cellular indexing of transcriptomes and epitopes by sequencing) and functional assays. We found significant depletion of B-cell populations with low expression of MCL-1 relative to other immune cells, attended by extensive transcriptomic changes. By contrast, there was less impact on circulating T cells and natural killer (NK) cells, with no changes in their subset composition, transcriptome, or function following venetoclax treatment. Our data indicate that venetoclax has minimal impact on circulating T or NK cells, supporting the rationale of combining this BH3 mimetic drug with cancer immunotherapies for more durable antitumor responses.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022008221","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T21:08:11Z","timestamp":1671138491000},"page":"2733-2745","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Venetoclax treatment in patients with cancer has limited impact on circulating T and NK cells"],"prefix":"10.1182","volume":"7","author":[{"given":"Charis E.","family":"Teh","sequence":"first","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4813-0827","authenticated-orcid":false,"given":"Hongke","family":"Peng","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7745-9755","authenticated-orcid":false,"given":"Meng-Xiao","family":"Luo","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3963-0360","authenticated-orcid":false,"given":"Tania","family":"Tan","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7258-7272","authenticated-orcid":false,"given":"Marie","family":"Trussart","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"3School of Mathematics and Statistics, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3522-4533","authenticated-orcid":false,"given":"Lauren J.","family":"Howson","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2162-3288","authenticated-orcid":false,"given":"Chong Chyn","family":"Chua","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"4Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia"},{"name":"5Clinical Haematology, The Alfred Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7166-1728","authenticated-orcid":false,"given":"Christine","family":"Muttiah","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"6The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9711-9769","authenticated-orcid":false,"given":"Fiona","family":"Brown","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"4Australian Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7383-0609","authenticated-orcid":false,"given":"Matthew E.","family":"Ritchie","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7514-3298","authenticated-orcid":false,"given":"Andrew H.","family":"Wei","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"6The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"7Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"6The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"7Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4697-7410","authenticated-orcid":false,"given":"Vanessa L.","family":"Bryant","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"6The Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"7Department of Clinical Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9386-2416","authenticated-orcid":false,"given":"Geoffrey J.","family":"Lindeman","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"},{"name":"6The Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"8Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3101-4873","authenticated-orcid":false,"given":"David C. S.","family":"Huang","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Thijssen","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8457-8242","authenticated-orcid":false,"given":"Daniel H. D.","family":"Gray","sequence":"additional","affiliation":[{"name":"1Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia"},{"name":"2Department of Medical Biology, The University of Melbourne, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2023,6,15]]},"reference":[{"issue":"2","key":"2023062614030834700_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"6","key":"2023062614030834700_bib2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023062614030834700_bib3","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"2023062614030834700_bib4","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"2023062614030834700_bib5","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023062614030834700_bib6","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"2","key":"2023062614030834700_bib7","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/S1470-2045(18)30010-X","article-title":"Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study","volume":"19","author":"DiNardo","year":"2018","journal-title":"Lancet Oncol"},{"issue":"15","key":"2023062614030834700_bib8","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2023062614030834700_bib9","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1182\/blood.2020006785","article-title":"BCL2 and MCL1 inhibitors for hematologic malignancies","volume":"138","author":"Roberts","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2023062614030834700_bib10","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1038\/cdd.2017.30","article-title":"Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in\u00a0vitro and in\u00a0vivo","volume":"24","author":"Carrington","year":"2017","journal-title":"Cell Death Differ"},{"issue":"6","key":"2023062614030834700_bib11","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/leu.2014.1","article-title":"Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199","volume":"28","author":"Khaw","year":"2014","journal-title":"Leukemia"},{"issue":"11","key":"2023062614030834700_bib12","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41419-021-04285-4","article-title":"Venetoclax imparts distinct cell death sensitivity and adaptivity patterns in T cells","volume":"12","author":"Ludwig","year":"2021","journal-title":"Cell Death Dis"},{"issue":"1","key":"2023062614030834700_bib13","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2159-8290.CD-19-0759","article-title":"Venetoclax increases intratumoral effector T cells and antitumor efficacy in combination with immune checkpoint blockade","volume":"11","author":"Kohlhapp","year":"2021","journal-title":"Cancer Discov"},{"issue":"23","key":"2023062614030834700_bib14","doi-asserted-by":"crossref","first-page":"5410","DOI":"10.1182\/bloodadvances.2021004861","article-title":"Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia","volume":"5","author":"Kater","year":"2021","journal-title":"Blood Adv"},{"issue":"19","key":"2023062614030834700_bib15","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1182\/bloodadvances.2020002810","article-title":"Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy","volume":"4","author":"Davis","year":"2020","journal-title":"Blood Adv"},{"issue":"17","key":"2023062614030834700_bib16","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1182\/bloodadvances.2019000360","article-title":"Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment","volume":"3","author":"de Weerdt","year":"2019","journal-title":"Blood Adv"},{"issue":"7","key":"2023062614030834700_bib17","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1038\/s41409-021-01245-6","article-title":"Venetoclax does not impair activated T-cell proliferation","volume":"56","author":"Siblany","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"2","key":"2023062614030834700_bib18","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/10428194.2021.1986217","article-title":"Impact of venetoclax monotherapy on the quality of life of patients with relapsed or refractory chronic lymphocytic leukemia: results from the phase 3b VENICE II trial","volume":"63","author":"Cochrane","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"30","key":"2023062614030834700_bib19","doi-asserted-by":"crossref","first-page":"3506","DOI":"10.1200\/JCO.20.00572","article-title":"Chemotherapy and Venetoclax in Elderly Acute Myeloid Leukemia Trial (CAVEAT): a phase Ib dose-escalation study of venetoclax combined with modified intensive chemotherapy","volume":"38","author":"Chua","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2023062614030834700_bib20","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2159-8290.CD-18-1151","article-title":"A\u00a0phase Ib dose-escalation and expansion study of the BCL2 Inhibitor venetoclax combined with tamoxifen in ER and BCL2-positive metastatic breast cancer","volume":"9","author":"Lok","year":"2019","journal-title":"Cancer Discov"},{"issue":"7","key":"2023062614030834700_bib21","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/s41418-020-0498-z","article-title":"Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells","volume":"27","author":"Teh","year":"2020","journal-title":"Cell Death Differ"},{"issue":"8","key":"2023062614030834700_bib22","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/bioinformatics\/btw777","article-title":"Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R","volume":"33","author":"McCarthy","year":"2017","journal-title":"Bioinformatics"},{"issue":"13","key":"2023062614030834700_bib23","doi-asserted-by":"crossref","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","article-title":"Integrated analysis of multimodal single-cell data","volume":"184","author":"Hao","year":"2021","journal-title":"Cell"},{"issue":"12","key":"2023062614030834700_bib24","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"issue":"1","key":"2023062614030834700_bib25","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"issue":"9","key":"2023062614030834700_bib26","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1038\/nprot.2007.297","article-title":"Measuring lymphocyte proliferation, survival and differentiation using CFSE time-series data","volume":"2","author":"Hawkins","year":"2007","journal-title":"Nat Protoc"},{"issue":"7","key":"2023062614030834700_bib27","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"issue":"9","key":"2023062614030834700_bib28","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T\u00a0cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2023062614030834700_bib29","doi-asserted-by":"crossref","first-page":"491","DOI":"10.2217\/imt-2017-0147","article-title":"Obinutuzumab induces depletion of NK cells in patients with chronic lymphocytic leukemia","volume":"10","author":"Garcia-Munoz","year":"2018","journal-title":"Immunotherapy"},{"key":"2023062614030834700_bib30","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.3389\/fimmu.2019.02832","article-title":"Long-term ibrutinib therapy reverses CD8(+) T cell exhaustion in B cell chronic lymphocytic leukaemia","volume":"10","author":"Parry","year":"2019","journal-title":"Front Immunol"},{"issue":"14","key":"2023062614030834700_bib31","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1182\/bloodadvances.2022007034","article-title":"Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4\u00a0T cells","volume":"6","author":"van Bruggen","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2023062614030834700_bib32","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1182\/blood.2020009081","article-title":"Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production","volume":"138","author":"Lee","year":"2021","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2733\/2060183\/blooda_adv-2022-008221-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/7\/12\/2733\/2060183\/blooda_adv-2022-008221-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T14:03:50Z","timestamp":1687788230000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/7\/12\/2733\/493732\/Venetoclax-treatment-in-patients-with-cancer-has"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,15]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,6,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022008221","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,15]]}}}